Immunovant (IMVT) Other Non Operating Income (2018 - 2026)
Immunovant's (IMVT) quarterly Other Non Operating Income came in at $798000.0 in Q1 2026, down 25.49% YoY from $1.1 million in Q1 2025, and up 1577.78% on a QoQ basis from -$54000.0 in Q4 2025.
Immunovant (IMVT) Other Non Operating Income (2018 - 2026) Analysis & Trends
Immunovant (IMVT) has 9 years of Other Non Operating Income data on file, last reported at $798000.0 in Q1 2026.
- Quarterly Other Non Operating Income fell 25.49% year-over-year to $798000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.2 million (up 364.04% YoY) and the FY2026 annual result came in at $2.2 million, up 363.06% from the prior year.
- Other Non Operating Income grew to $798000.0 in Q1 2026, from -$54000.0 in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $1.2 million in Q2 2025 to a low of -$2.6 million in Q1 2024.
- A 5-year average of $84235.3 and a median of $354000.0 in 2022 frame the typical range for Other Non Operating Income.
- Annual changes were most pronounced in 2022 — Other Non Operating Income plunged 1441.23% — and 2025, when it soared 4139.29%.
- Tracing IMVT's Other Non Operating Income over 5 years: stood at -$1.8 million in 2022, then jumped by 162.27% to $1.1 million in 2023, then slumped by 214.99% to -$1.3 million in 2024, then jumped by 95.71% to -$54000.0 in 2025, then jumped by 1577.78% to $798000.0 in 2026.
- The last three Other Non Operating Income figures came in at $798000.0 (Q1 2026), -$54000.0 (Q4 2025), and $250000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Immunovant | 8.63 Bn | 7.83 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4,000.00 |
| Mar 31, 2026 | 798,000.00 |
| Dec 31, 2025 | -54,000.00 |
| Sep 30, 2025 | 250,000.00 |
| Jun 30, 2025 | 1.19 Mn |
| Mar 31, 2025 | 1.07 Mn |
| Dec 31, 2024 | -1.26 Mn |
| Sep 30, 2024 | 629,000.00 |
| Jun 30, 2024 | 28,000.00 |
| Mar 31, 2024 | -2.59 Mn |
| Dec 31, 2023 | 1.09 Mn |
| Sep 30, 2023 | 20,000.00 |
| Jun 30, 2023 | 464,000.00 |
| Mar 31, 2023 | 356,000.00 |
| Dec 31, 2022 | -1.76 Mn |
| Sep 30, 2022 | 793,000.00 |
| Jun 30, 2022 | 354,000.00 |
| Mar 31, 2022 | 44,000.00 |
| Dec 31, 2021 | -114,000.00 |
| Sep 30, 2021 | -84,000.00 |